Compared with the non-recurrence group, patients in the recurrence group had higher BMI, more masses, more non-luminal types, a tendency to grade 3 pathology, advanced clinical stage, a higher risk of lymph node metastasis, positive vascular cancer thrombus, positive tumor perineural invasion, higher NLR, more positive HER2, and more common Ki-67 > 14%. This evidence concerns the gene ERBB2 and vascular cancer.